Kyowa Kirin Co., Ltd.

This study tests a new drug called KK8123 for adults with X-linked hypophosphatemia (XLH), a rare genetic condition that causes low phosphate levels and bone problems. The trial has two parts: first, finding the right dose, then checking long-term safety. About 24 adults aged 18 …

This study tracks 15 adults with mycosis fungoides or Sezary syndrome who receive mogamulizumab, a targeted antibody therapy, in everyday medical practice. Researchers will record side effects and measure how well the drug controls the cancer using a standard scoring system. The …

This early-phase study tests a new drug called KK2260 in people with advanced solid tumors (cancers that have spread). The main goals are to find a safe dose and check for side effects. The study will first include people with any advanced cancer, then focus on those with esophag…

This early-stage study tests a new drug called KK3910 for safety in 160 people. First, healthy volunteers get a single dose. Then, patients with high blood pressure get multiple doses. The goal is to see if the drug is safe and how the body processes it.

This early-phase study tests a new drug called KK2845 in adults whose acute myeloid leukemia has returned or not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 72 participants will take part in two stages: first to find th…

This early-phase study tests a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 101 people with certain cancer…